|
Oct 16
|
Multiple Tailwinds Lifted argenx SE (ARGX) in Q3
|
|
Oct 15
|
Argenx Says New Data on its Generalized Myasthenia Gravis Treatments Demonstrate 'Sustained Responses'
|
|
Oct 15
|
argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions
|
|
Oct 9
|
argenx SE (ARGNF) Q2 2024 Earnings Call Highlights: Strong Financial Performance Amid ...
|
|
Oct 7
|
Zacks.com featured highlights include Argenx SE Alphatec and Olin
|
|
Sep 25
|
Amgen stock falls on lackluster drug data
|
|
Sep 25
|
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases
|
|
Aug 29
|
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
|
|
Aug 28
|
argenx to Present at Upcoming Investor Conferences
|
|
Jul 30
|
Argenx (ARGX) Upgraded to Buy: Here's What You Should Know
|
|
Jul 25
|
argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
|
|
Jul 16
|
What Made argenx SE (ARGX) Rise in Q2?
|
|
Jul 16
|
argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
|
|
Jul 16
|
Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
|
|
Jun 25
|
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting
|
|
Jun 25
|
Argenx (ARGX) Surges 11.7%: Is This an Indication of Further Gains?
|
|
Jun 24
|
Argenx Surges After Its Bread-And-Butter Drug Wins Another FDA Approval
|
|
Jun 24
|
FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder
|
|
Jun 24
|
FDA approves argenx’s VYVGART Hytrulo for CIDP treatment
|
|
Jun 21
|
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
|